# Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a

> **NCT02218736** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 163 (actual)

## Conditions studied

- ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)

## Interventions

- **DRUG:** CERC-501
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02218736
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-11-01
- **Final completion:** 2017-12-01
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2019-01-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218736, "Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02218736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*